Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?

This article was originally published in The Pink Sheet Daily

Executive Summary

With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.


Related Content

A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers
Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support
Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts